Review



apv  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Merck & Co apv
    Neuronal activation triggers Matrix Metalloproteinase (MMP)-dependent PCDH9 cleavage in primary neurons. (A) Experimental scheme (top panel) and representative PCDH9 Western blot (bottom panels) of primary neurons treated with 20 <t>μM</t> <t>NMDA</t> for 30 min, 1 h or 2 h. At short exposures (bottom left panel), two full-length PCDH9 isoforms (PCDH FL; ~130 and ~180 kDa; indicated by arrowheads) are detected, as previously reported ( ; ). At longer exposure time (right bottom panel), additional lower molecular-weights bands become visible, including one above 30 kDa whose level changes with NMDA treatment (putative PCDH9 C-terminal fragment, PCDH9 CTF). GAPDH was used as a loading control. (B) Quantifications of PCDH9 FL and PCDH9 CTF levels from A. Protein levels were normalized to GAPDH. n = 3-6 independent cultures. (C) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the MMP inhibitor GM6001 (5 h prior to NMDA exposure, 6 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (D) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons treated 1 h with glutamate (glu), bicuculline (BIC) or tetrodotoxin (TTX). n = 3-7 independent cultures. (E) Representative WB and corresponding quantification of PCDH9 CTF levels in rat primary neurons pretreated with the NMDAR antagonist <t>APV</t> (1 h prior to NMDA exposure, 2 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (F) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the NMDAR antagonist APV (1 h prior to glutamate exposure, 2 h total) before exposure to glutamate (1 h). n = 3 independent cultures. The bands corresponding to full-length (FL) PCDH9 are also displayed. WB quantifications are presented as protein levels normalized to GAPDH. Mean ± SD is shown. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn's multiple comparisons test against untreated controls. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Apv, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/pmc12890670-37-13-16?v=Merck+%26+Co
    Average 86 stars, based on 1 article reviews
    apv - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Neuronal activity drives PCDH9 cleavage and nuclear translocation to coordinate structural and functional remodeling"

    Article Title: Neuronal activity drives PCDH9 cleavage and nuclear translocation to coordinate structural and functional remodeling

    Journal: Frontiers in Cellular Neuroscience

    doi: 10.3389/fncel.2025.1736960

    Neuronal activation triggers Matrix Metalloproteinase (MMP)-dependent PCDH9 cleavage in primary neurons. (A) Experimental scheme (top panel) and representative PCDH9 Western blot (bottom panels) of primary neurons treated with 20 μM NMDA for 30 min, 1 h or 2 h. At short exposures (bottom left panel), two full-length PCDH9 isoforms (PCDH FL; ~130 and ~180 kDa; indicated by arrowheads) are detected, as previously reported ( ; ). At longer exposure time (right bottom panel), additional lower molecular-weights bands become visible, including one above 30 kDa whose level changes with NMDA treatment (putative PCDH9 C-terminal fragment, PCDH9 CTF). GAPDH was used as a loading control. (B) Quantifications of PCDH9 FL and PCDH9 CTF levels from A. Protein levels were normalized to GAPDH. n = 3-6 independent cultures. (C) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the MMP inhibitor GM6001 (5 h prior to NMDA exposure, 6 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (D) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons treated 1 h with glutamate (glu), bicuculline (BIC) or tetrodotoxin (TTX). n = 3-7 independent cultures. (E) Representative WB and corresponding quantification of PCDH9 CTF levels in rat primary neurons pretreated with the NMDAR antagonist APV (1 h prior to NMDA exposure, 2 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (F) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the NMDAR antagonist APV (1 h prior to glutamate exposure, 2 h total) before exposure to glutamate (1 h). n = 3 independent cultures. The bands corresponding to full-length (FL) PCDH9 are also displayed. WB quantifications are presented as protein levels normalized to GAPDH. Mean ± SD is shown. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn's multiple comparisons test against untreated controls. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Figure Legend Snippet: Neuronal activation triggers Matrix Metalloproteinase (MMP)-dependent PCDH9 cleavage in primary neurons. (A) Experimental scheme (top panel) and representative PCDH9 Western blot (bottom panels) of primary neurons treated with 20 μM NMDA for 30 min, 1 h or 2 h. At short exposures (bottom left panel), two full-length PCDH9 isoforms (PCDH FL; ~130 and ~180 kDa; indicated by arrowheads) are detected, as previously reported ( ; ). At longer exposure time (right bottom panel), additional lower molecular-weights bands become visible, including one above 30 kDa whose level changes with NMDA treatment (putative PCDH9 C-terminal fragment, PCDH9 CTF). GAPDH was used as a loading control. (B) Quantifications of PCDH9 FL and PCDH9 CTF levels from A. Protein levels were normalized to GAPDH. n = 3-6 independent cultures. (C) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the MMP inhibitor GM6001 (5 h prior to NMDA exposure, 6 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (D) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons treated 1 h with glutamate (glu), bicuculline (BIC) or tetrodotoxin (TTX). n = 3-7 independent cultures. (E) Representative WB and corresponding quantification of PCDH9 CTF levels in rat primary neurons pretreated with the NMDAR antagonist APV (1 h prior to NMDA exposure, 2 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (F) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the NMDAR antagonist APV (1 h prior to glutamate exposure, 2 h total) before exposure to glutamate (1 h). n = 3 independent cultures. The bands corresponding to full-length (FL) PCDH9 are also displayed. WB quantifications are presented as protein levels normalized to GAPDH. Mean ± SD is shown. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn's multiple comparisons test against untreated controls. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Techniques Used: Activation Assay, Western Blot, Control



    Similar Products

    2 amino 5 phosphonopentanoic acid d apv hellobio cat  (Alomone Labs)
    94
    Alomone Labs 2 amino 5 phosphonopentanoic acid d apv hellobio cat
    2 Amino 5 Phosphonopentanoic Acid D Apv Hellobio Cat, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/pm41533510-293-92-110?v=Alomone+Labs
    Average 94 stars, based on 1 article reviews
    2 amino 5 phosphonopentanoic acid d apv hellobio cat - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    dl apv  (Tocris)
    96
    Tocris dl apv
    Dl Apv, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/bio_rxiv__64898__2026__04__13__718178-341-13-14?v=Tocris
    Average 96 stars, based on 1 article reviews
    dl apv - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    d apv  (Tocris)
    96
    Tocris d apv
    D Apv, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/10__1038_slash_s41467___026___70962___7-493-22-23?v=Tocris
    Average 96 stars, based on 1 article reviews
    d apv - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    2 amino 5phosphonovaleric acid apv  (Hello Bio Inc)
    86
    Hello Bio Inc 2 amino 5phosphonovaleric acid apv
    2 Amino 5phosphonovaleric Acid Apv, supplied by Hello Bio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/10__3390_slash_physiologia6010018-152-27-30?v=Hello+Bio+Inc
    Average 86 stars, based on 1 article reviews
    2 amino 5phosphonovaleric acid apv - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    apv  (Tocris)
    96
    Tocris apv
    Apv, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/pm41708752-326-3-4?v=Tocris
    Average 96 stars, based on 1 article reviews
    apv - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    14 3 d apv tocris  (Tocris)
    96
    Tocris 14 3 d apv tocris
    14 3 D Apv Tocris, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/pm41709459-587-89-91?v=Tocris
    Average 96 stars, based on 1 article reviews
    14 3 d apv tocris - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    d-2-amino-5-phosphonopentanoic acid d-apv  (Tocris)
    90
    Tocris d-2-amino-5-phosphonopentanoic acid d-apv
    D 2 Amino 5 Phosphonopentanoic Acid D Apv, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/pmc12220725-61-57-62?v=Tocris
    Average 90 stars, based on 1 article reviews
    d-2-amino-5-phosphonopentanoic acid d-apv - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    apv  (Merck & Co)
    86
    Merck & Co apv
    Neuronal activation triggers Matrix Metalloproteinase (MMP)-dependent PCDH9 cleavage in primary neurons. (A) Experimental scheme (top panel) and representative PCDH9 Western blot (bottom panels) of primary neurons treated with 20 <t>μM</t> <t>NMDA</t> for 30 min, 1 h or 2 h. At short exposures (bottom left panel), two full-length PCDH9 isoforms (PCDH FL; ~130 and ~180 kDa; indicated by arrowheads) are detected, as previously reported ( ; ). At longer exposure time (right bottom panel), additional lower molecular-weights bands become visible, including one above 30 kDa whose level changes with NMDA treatment (putative PCDH9 C-terminal fragment, PCDH9 CTF). GAPDH was used as a loading control. (B) Quantifications of PCDH9 FL and PCDH9 CTF levels from A. Protein levels were normalized to GAPDH. n = 3-6 independent cultures. (C) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the MMP inhibitor GM6001 (5 h prior to NMDA exposure, 6 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (D) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons treated 1 h with glutamate (glu), bicuculline (BIC) or tetrodotoxin (TTX). n = 3-7 independent cultures. (E) Representative WB and corresponding quantification of PCDH9 CTF levels in rat primary neurons pretreated with the NMDAR antagonist <t>APV</t> (1 h prior to NMDA exposure, 2 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (F) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the NMDAR antagonist APV (1 h prior to glutamate exposure, 2 h total) before exposure to glutamate (1 h). n = 3 independent cultures. The bands corresponding to full-length (FL) PCDH9 are also displayed. WB quantifications are presented as protein levels normalized to GAPDH. Mean ± SD is shown. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn's multiple comparisons test against untreated controls. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Apv, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apv/pmc12890670-37-13-16?v=Merck+%26+Co
    Average 86 stars, based on 1 article reviews
    apv - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Neuronal activation triggers Matrix Metalloproteinase (MMP)-dependent PCDH9 cleavage in primary neurons. (A) Experimental scheme (top panel) and representative PCDH9 Western blot (bottom panels) of primary neurons treated with 20 μM NMDA for 30 min, 1 h or 2 h. At short exposures (bottom left panel), two full-length PCDH9 isoforms (PCDH FL; ~130 and ~180 kDa; indicated by arrowheads) are detected, as previously reported ( ; ). At longer exposure time (right bottom panel), additional lower molecular-weights bands become visible, including one above 30 kDa whose level changes with NMDA treatment (putative PCDH9 C-terminal fragment, PCDH9 CTF). GAPDH was used as a loading control. (B) Quantifications of PCDH9 FL and PCDH9 CTF levels from A. Protein levels were normalized to GAPDH. n = 3-6 independent cultures. (C) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the MMP inhibitor GM6001 (5 h prior to NMDA exposure, 6 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (D) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons treated 1 h with glutamate (glu), bicuculline (BIC) or tetrodotoxin (TTX). n = 3-7 independent cultures. (E) Representative WB and corresponding quantification of PCDH9 CTF levels in rat primary neurons pretreated with the NMDAR antagonist APV (1 h prior to NMDA exposure, 2 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (F) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the NMDAR antagonist APV (1 h prior to glutamate exposure, 2 h total) before exposure to glutamate (1 h). n = 3 independent cultures. The bands corresponding to full-length (FL) PCDH9 are also displayed. WB quantifications are presented as protein levels normalized to GAPDH. Mean ± SD is shown. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn's multiple comparisons test against untreated controls. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Journal: Frontiers in Cellular Neuroscience

    Article Title: Neuronal activity drives PCDH9 cleavage and nuclear translocation to coordinate structural and functional remodeling

    doi: 10.3389/fncel.2025.1736960

    Figure Lengend Snippet: Neuronal activation triggers Matrix Metalloproteinase (MMP)-dependent PCDH9 cleavage in primary neurons. (A) Experimental scheme (top panel) and representative PCDH9 Western blot (bottom panels) of primary neurons treated with 20 μM NMDA for 30 min, 1 h or 2 h. At short exposures (bottom left panel), two full-length PCDH9 isoforms (PCDH FL; ~130 and ~180 kDa; indicated by arrowheads) are detected, as previously reported ( ; ). At longer exposure time (right bottom panel), additional lower molecular-weights bands become visible, including one above 30 kDa whose level changes with NMDA treatment (putative PCDH9 C-terminal fragment, PCDH9 CTF). GAPDH was used as a loading control. (B) Quantifications of PCDH9 FL and PCDH9 CTF levels from A. Protein levels were normalized to GAPDH. n = 3-6 independent cultures. (C) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the MMP inhibitor GM6001 (5 h prior to NMDA exposure, 6 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (D) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons treated 1 h with glutamate (glu), bicuculline (BIC) or tetrodotoxin (TTX). n = 3-7 independent cultures. (E) Representative WB and corresponding quantification of PCDH9 CTF levels in rat primary neurons pretreated with the NMDAR antagonist APV (1 h prior to NMDA exposure, 2 h total) before exposure to NMDA (1 h). n = 3 independent cultures. (F) Representative WB and corresponding quantification of PCDH9 CTF levels in primary neurons pretreated with the NMDAR antagonist APV (1 h prior to glutamate exposure, 2 h total) before exposure to glutamate (1 h). n = 3 independent cultures. The bands corresponding to full-length (FL) PCDH9 are also displayed. WB quantifications are presented as protein levels normalized to GAPDH. Mean ± SD is shown. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn's multiple comparisons test against untreated controls. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Article Snippet: DIV15 neurons were treated with the following reagents: NMDA (20 μM; Sigma- Aldrich), APV (100 μM; Merck), glutamate (50 μM; Tocris), bicuculline (40 μM; Sigma-Aldrich), tetrodotoxin (2 μM; Tocris), GM6001 (10 μM; Tocris).

    Techniques: Activation Assay, Western Blot, Control